Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus DECLOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus DECLOMYCIN.
ACHROMYCIN V vs DECLOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
250-500 mg orally every 6 hours
150 mg orally every 6 hours or 300 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic